ANAB analyst estimates
AnaptysBio (ANAB) analyst ratings, the average price target and its range, and every firm's latest call.
ANAB analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Sep 23, 2026 | Leerink Partners | AnaptysBio price target lowered to $81 from $90 at Leerink | $81.00 |
| Sep 22, 2026 | H.C. Wainwright | H.C. Wainwright Reiterates Buy Rating on AnaptysBio (ANAB) | $95.00 |
| Aug 31, 2026 | Wolfe Research | Wolfe Research Reiterates Outperform Rating on AnaptysBio (ANAB) | $78.00 |
| Aug 25, 2026 | Scotiabank | AnaptysBio (ANAB) PT Lowered to $70 at TD Cowen | $70.00 |
| May 15, 2026 | Leerink Partners | AnaptysBio price target raised to $90 from $85 at Leerink | $90.00 |
| May 13, 2026 | Barclays | AnaptysBio price target raised to $75 from $63 at Barclays | $75.00 |
| May 13, 2026 | UBS | AnaptysBio price target raised to $76 from $60 at UBS | $76.00 |
| Apr 28, 2026 | Leerink Partners | AnaptysBio price target raised to $85 from $66 at Leerink | $85.00 |
| Apr 21, 2026 | UBS | AnaptysBio price target lowered to $60 from $90 at UBS | $60.00 |
| Mar 6, 2026 | Truist Financial | AnaptysBio (ANAB) PT Raised to $50 at Truist Securities on improved outlook for Jemperli | $50.00 |
| Mar 5, 2026 | Stifel Nicolaus | AnaptysBio (ANAB) PT Raised to $85 at Stifel After Q4 Update | $85.00 |
| Mar 4, 2026 | H.C. Wainwright | AnaptysBio (ANAB) PT Raised to $66 at H.C. Wainwright | $66.00 |
| Jan 7, 2026 | UBS | UBS Assumes AnaptysBio (ANAB) at Buy | $70.00 |
| Dec 18, 2025 | Guggenheim | AnaptysBio price target raised to $140 from $100 at Guggenheim | $140.00 |
| Dec 17, 2025 | Barclays | AnaptysBio price target lowered to $55 from $70 at Barclays | $55.00 |
- 12 firms rate ANAB: 11 buy, 1 hold, 0 sell.
- The average price target is $79.17 from 6 analysts, from $70.00 to $95.00.
Updated 2026-11-02 17:52 UTC